粪便微生物群移植能治愈肠易激综合征吗？
Can fecal microbiota transplantation cure irritable bowel syndrome?
作者信息
Halkjær Sofie Ingdam, Boolsen Anders Watt, Günther Stig, Christensen Alice Højer, Petersen Andreas Munk
机构信息
Sofie Ingdam Halkjær, Andreas Munk Petersen, Department of Gastroenterology, Copenhagen University Hospital Hvidovre, 2650 Copenhagen, Denmark.
出版信息
World J Gastroenterol. 2017 Jun 14;23(22):4112-4120. doi: 10.3748/wjg.v23.i22.4112.
AIM
To verify the utility of treatment with fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome (IBS).
METHODS
We searched EMBASE, Cochrane Library and PubMed in March, 2017. The reviewed literature was based on two systematic searches in each of the databases. The MeSH terms used were IBS and fecal microbiota transplantation and the abbreviations IBS and FMT. Reference lists from the articles were reviewed to identify additional pertinent articles.
RESULTS
A total of six conference abstracts, one case report, one letter to the editor, and one clinical review were included. In the final analysis, treatment of 48 patients was evaluated. Treatment revealed an improvement in 58% of cases. The varying structure of the nine included studies must be taken into consideration.
CONCLUSION
Data on FMT and IBS are too limited to draw sufficient conclusions. Standardized double blinded randomized clinical trials need to be carried out to evaluate the effect of FMT on IBS.
目的
验证粪便微生物群移植（FMT）治疗肠易激综合征（IBS）患者的效用。
方法
我们于2017年3月检索了EMBASE、Cochrane图书馆和PubMed。所综述的文献基于在每个数据库中进行的两次系统检索。使用的医学主题词为肠易激综合征和粪便微生物群移植以及缩写词IBS和FMT。对文章的参考文献列表进行了审查，以识别其他相关文章。
结果
共纳入6篇会议摘要、1篇病例报告、1篇致编辑的信和1篇临床综述。在最终分析中，对48例患者的治疗进行了评估。治疗显示58%的病例有改善。必须考虑9项纳入研究的不同结构。
结论
关于粪便微生物群移植和肠易激综合征的数据非常有限，无法得出充分的结论。需要开展标准化的双盲随机临床试验来评估粪便微生物群移植对肠易激综合征的疗效。
Zotero 插件